Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes.

Beta cell dysfunction Cardiovascular disease Chronic kidney disease Cluster analysis Heart failure Lipidomics Mortality Polygenic risk score Type 2 diabetes mellitus

Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
12 2022
Historique:
received: 28 02 2022
accepted: 25 04 2022
pubmed: 29 6 2022
medline: 5 11 2022
entrez: 28 6 2022
Statut: ppublish

Résumé

We sought to subtype South East Asian patients with type 2 diabetes by de novo cluster analysis on clinical variables, and to determine whether the novel subgroups carry distinct genetic and lipidomic features as well as differential cardio-renal risks. Analysis by k-means algorithm was performed in 687 participants with recent-onset diabetes in Singapore. Genetic risk for beta cell dysfunction was assessed by polygenic risk score. We used a discovery-validation approach for the lipidomics study. Risks for cardio-renal complications were studied by survival analysis. Cluster analysis identified three novel diabetic subgroups, i.e. mild obesity-related diabetes (MOD, 45%), mild age-related diabetes with insulin insufficiency (MARD-II, 36%) and severe insulin-resistant diabetes with relative insulin insufficiency (SIRD-RII, 19%). Compared with the MOD subgroup, MARD-II had a higher polygenic risk score for beta cell dysfunction. The SIRD-RII subgroup had higher levels of sphingolipids (ceramides and sphingomyelins) and glycerophospholipids (phosphatidylethanolamine and phosphatidylcholine), whereas the MARD-II subgroup had lower levels of sphingolipids and glycerophospholipids but higher levels of lysophosphatidylcholines. Over a median of 7.3 years follow-up, the SIRD-RII subgroup had the highest risks for incident heart failure and progressive kidney disease, while the MARD-II subgroup had moderately elevated risk for kidney disease progression. Cluster analysis on clinical variables identified novel subgroups with distinct genetic, lipidomic signatures and varying cardio-renal risks in South East Asian participants with type 2 diabetes. Our study suggests that this easily actionable approach may be adapted in other ethnic populations to stratify the heterogeneous type 2 diabetes population for precision medicine.

Identifiants

pubmed: 35763031
doi: 10.1007/s00125-022-05741-2
pii: 10.1007/s00125-022-05741-2
pmc: PMC9630229
doi:

Substances chimiques

Insulin 0
Sphingolipids 0
Glycerophospholipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2146-2156

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Diabetologia. 2022 Jan;65(1):65-78
pubmed: 34689214
Nat Rev Endocrinol. 2013 Sep;9(9):537-47
pubmed: 23712250
Diabetologia. 2020 Sep;63(9):1671-1693
pubmed: 32556613
Diabetes. 2020 Oct;69(10):2086-2093
pubmed: 32843567
Diabetes Obes Metab. 2020 Sep;22(9):1537-1547
pubmed: 32314525
Cell Metab. 2021 Aug 3;33(8):1519-1545
pubmed: 34289375
Diabetes Care. 2021 May;44(5):1203-1210
pubmed: 33707304
Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694
pubmed: 31345776
Lancet Diabetes Endocrinol. 2019 Jun;7(6):442-451
pubmed: 31047901
Nephrol Dial Transplant. 2017 Oct 01;32(10):1697-1704
pubmed: 27448675
J Clin Endocrinol Metab. 2022 Jan 1;107(1):e178-e187
pubmed: 34415993
J Cell Mol Med. 2019 Feb;23(2):702-710
pubmed: 30402908
Circulation. 2016 Nov 22;134(21):1637-1650
pubmed: 27756783
J Clin Endocrinol Metab. 2015 Apr;100(4):1586-93
pubmed: 25636050
Diabetes. 2021 Nov;70(11):2683-2693
pubmed: 34376475
Diabetes. 2021 May;70(5):1198-1208
pubmed: 33608423
Cell Metab. 2021 Jul 6;33(7):1293-1306
pubmed: 34233172
Diabetes Care. 2020 Sep;43(9):2161-2168
pubmed: 32910776
Sci Rep. 2020 Jun 11;10(1):9450
pubmed: 32528078
Nature. 2020 Jun;582(7811):240-245
pubmed: 32499647
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
Diabetologia. 2017 May;60(5):793-799
pubmed: 28175964
Am J Kidney Dis. 2021 Jan;77(1):94-109
pubmed: 33121838
J Clin Med. 2020 Jul 02;9(7):
pubmed: 32630741
Diabetologia. 2018 Jun;61(6):1249-1260
pubmed: 29392352
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Lancet Diabetes Endocrinol. 2019 Jan;7(1):9-11
pubmed: 30577891
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Ann Intern Med. 2003 Nov 18;139(10):802-9
pubmed: 14623617
Diabetologia. 2021 Sep;64(9):1973-1981
pubmed: 34059937
Endocr Rev. 2021 Sep 28;42(5):528-583
pubmed: 34180979
BMJ Open Diabetes Res Care. 2020 Aug;8(1):
pubmed: 32816869
Diabetologia. 2021 Sep;64(9):1982-1989
pubmed: 34110439
Diabetes Care. 2021 Feb;44(2):571-577
pubmed: 33293346
PLoS Med. 2018 Sep 21;15(9):e1002654
pubmed: 30240442
Diabetes Care. 2020 Mar;43(3):625-633
pubmed: 31862788
J Clin Endocrinol Metab. 2021 Apr 23;106(5):e2106-e2115
pubmed: 33502458
Clin Chem. 2021 Nov 26;67(12):1640-1649
pubmed: 34568896
Diabetologia. 2022 Jan;65(1):206-215
pubmed: 34676424

Auteurs

Jiexun Wang (J)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Jian-Jun Liu (JJ)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Resham L Gurung (RL)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Sylvia Liu (S)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Janus Lee (J)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Yiamunaa M (Y)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Keven Ang (K)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Yi Ming Shao (YM)

Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Justin I-Shing Tang (JI)

Department of Medicine, Khoo Teck Puat Hospital, Singapore, Republic of Singapore.

Peter I Benke (PI)

Lipidomics Incubator, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.

Federico Torta (F)

Lipidomics Incubator, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.

Markus R Wenk (MR)

Lipidomics Incubator, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore.

Subramaniam Tavintharan (S)

Diabetes Centre, Admiralty Medical Centre, Singapore, Republic of Singapore.

Wern Ee Tang (WE)

National Healthcare Group Polyclinic, Singapore, Republic of Singapore.

Chee Fang Sum (CF)

Diabetes Centre, Admiralty Medical Centre, Singapore, Republic of Singapore.

Su Chi Lim (SC)

Diabetes Centre, Admiralty Medical Centre, Singapore, Republic of Singapore. lim.su.chi@ktph.com.sg.
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Republic of Singapore. lim.su.chi@ktph.com.sg.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Republic of Singapore. lim.su.chi@ktph.com.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH